Research news

Ivosidenib induces durable remission in nearly a third of patients with isocitrate dehydrogenase 1-mutated relapsed or refractory acute myeloid leukemia, phase 1 study data show.

Once-weekly treatment with carfilzomib at the maximum tolerated dose significantly delays disease progression compared with twice-weekly treatment at a lower dose in patients with relapsed or refractory multiple myeloma, study data show.

Women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer who have a midrange score on the 21-tumor gene assay may be spared adjuvant chemotherapy, phase III study data show.

Treatment with the combination of ibrutinib and rituximab results in better outcomes for patients with newly diagnosed or recurrent Waldenström macroglobulinemia than rituximab alone, phase III trial findings indicate.

The cost of metastatic colorectal cancer treatment in the USA is significantly more expensive than in Canada but does not achieve a greater survival benefit among patients, highlight findings reported at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

Women with head and neck cancer may be undertreated relative to their male counterparts, suggests research presented at the ASCO Annual Meeting 2018.

Reducing adjuvant treatment with trastuzumab from the current standard of 12 months to 6 months does not have a negative impact on disease-free survival in women with HER2-positive early breast cancer, PERSEPHONE trial data show.

Trial results suggest that cognitive behavioral therapy for insomnia is more effective than acupuncture for reducing the severity of insomnia symptoms in cancer survivors, although both approaches offer benefits.

The addition of nelarabine and an escalating dose of methotrexate to a standard chemotherapy regimen has achieved the best ever survival outcomes for children and young adults with a new diagnosis of T-cell acute lymphoblastic leukemia who are at risk for recurrence, researchers say.